



Clinical trial results:

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F) Summary

EudraCT number	2018-000184-89
Trial protocol	GB BE NL
Global end of trial date	28 December 2018

Results information

Result version number	v2 (current)
This version publication date	29 April 2020
First version publication date	17 July 2019
Version creation reason	• New data added to full data set Addition of secondary endpoints

Trial information

Trial identification

Sponsor protocol code	VX17-445-103
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03525548
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Vertex Pharmaceuticals Incorporated
Sponsor organisation address	50 Northern Avenue, Boston, Massachusetts, United States,
Public contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
Scientific contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002324-PIP01-17
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 February 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	28 December 2018
Global end of trial reached?	Yes
Global end of trial date	28 December 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F).

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 August 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 14
Country: Number of subjects enrolled	Netherlands: 12
Country: Number of subjects enrolled	United Kingdom: 14
Country: Number of subjects enrolled	United States: 73
Worldwide total number of subjects	113
EEA total number of subjects	40

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	33
Adults (18-64 years)	80
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was conducted in subjects with cystic fibrosis (CF) aged 12 years or older.

Period 1

Period 1 title	Triple Combination Treatment Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	TEZ/IVA
------------------	---------

Arm description:

Following a run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA for 4 weeks in the TC treatment period.

Arm type	Active comparator
Investigational medicinal product name	Placebo (matched to VX-445/TEZ/IVA)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo matched to VX-445/TEZ/IVA once daily in the morning.

Investigational medicinal product name	TEZ/IVA
Investigational medicinal product code	VX-661/VX-770
Other name	Tezacaftor/Ivacaftor fixed dose combination
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received TEZ/IVA once daily in the morning.

Investigational medicinal product name	IVA
Investigational medicinal product code	VX-770
Other name	Ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received IVA once daily in the evening.

Arm title	VX-445/TEZ/IVA TC
------------------	-------------------

Arm description:

Following a run-in period of 4 weeks with TEZ/IVA, subjects received VX-445/TEZ/IVA for 4 weeks in the TC treatment period.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	VX-445/TEZ/IVA
Investigational medicinal product code	VX-445/VX-661/VX-770
Other name	VX-445/Tezacaftor/Ivacaftor fixed dose combination
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received VX-445/TEZ/IVA once daily in the morning.

Investigational medicinal product name	Placebo (matched to TEZ/IVA)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo matched to TEZ/IVA once daily in the morning.

Investigational medicinal product name	IVA
Investigational medicinal product code	VX-770
Other name	Ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received IVA once daily in the evening.

Number of subjects in period 1^[1]	TEZ/IVA	VX-445/TEZ/IVA TC
Started	52	55
Completed	52	55

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: In the above disposition summary, data is presented for 107 subjects dosed in the TC treatment period. 6 subjects were included in the run-in period but were not dosed in TC treatment period. Therefore, the total enrolled subjects are 113 whereas the subjects reported in disposition and baseline are 107.

Baseline characteristics

Reporting groups

Reporting group title	TEZ/IVA
Reporting group description:	
Following a run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA for 4 weeks in the TC treatment period.	
Reporting group title	VX-445/TEZ/IVA TC
Reporting group description:	
Following a run-in period of 4 weeks with TEZ/IVA, subjects received VX-445/TEZ/IVA for 4 weeks in the TC treatment period.	

Reporting group values	TEZ/IVA	VX-445/TEZ/IVA TC	Total
Number of subjects	52	55	107
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	27.9	28.8	
standard deviation	± 10.8	± 11.5	-
Gender categorical Units: Subjects			
Female	28	31	59
Male	24	24	48
Ethnicity Units: Subjects			
Hispanic or Latino	3	2	5
Not Hispanic or Latino	49	52	101
Unknown or Not Reported	0	1	1
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	52	54	106
More than one race	0	0	0
Unknown or Not Reported	0	1	1
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)			
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.			
Units: Percentage points			
arithmetic mean	60.2	61.6	
standard deviation	± 14.4	± 15.4	-

End points

End points reporting groups

Reporting group title	TEZ/IVA
Reporting group description: Following a run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA for 4 weeks in the TC treatment period.	
Reporting group title	VX-445/TEZ/IVA TC
Reporting group description: Following a run-in period of 4 weeks with TEZ/IVA, subjects received VX-445/TEZ/IVA for 4 weeks in the TC treatment period.	

Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

End point title	Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
End point description: FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. FAS.	
End point type	Primary
End point timeframe: At Week 4	

End point values	TEZ/IVA	VX-445/TEZ/IVA TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	55		
Units: percentage points				
least squares mean (standard error)	0.4 (± 0.9)	10.4 (± 0.9)		

Statistical analyses

Statistical analysis title	Statistical Analysis
Comparison groups	TEZ/IVA v VX-445/TEZ/IVA TC
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed-effects model for repeated measure
Parameter estimate	Least Square (LS) mean difference
Point estimate	10

Confidence interval	
level	95 %
sides	2-sided
lower limit	7.4
upper limit	12.6

Secondary: Absolute Change in Sweat Chloride (SwCl)

End point title	Absolute Change in Sweat Chloride (SwCl)
End point description: Sweat samples were collected using an approved collection device. FAS.	
End point type	Secondary
End point timeframe: From Baseline at Week 4	

End point values	TEZ/IVA	VX-445/TEZ/IVA TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	55		
Units: millimole per liter (mmol/L)				
least squares mean (standard error)	1.7 (± 1.8)	-43.4 (± 1.7)		

Statistical analyses

Statistical analysis title	TEZ/IVA vs VX-445/TEZ/IVA TC
Comparison groups	VX-445/TEZ/IVA TC v TEZ/IVA
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed-effects model for repeated measure
Parameter estimate	LS mean difference
Point estimate	-45.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-50.1
upper limit	-40.1

Secondary: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

End point title	Absolute Change in Cystic Fibrosis Questionnaire-Revised
-----------------	--

End point description:

The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicate fewer symptoms and better health-related quality of life. FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 4

End point values	TEZ/IVA	VX-445/TEZ/IVA TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	55		
Units: units on a scale				
least squares mean (standard error)	-1.4 (± 2.0)	16.0 (± 2.0)		

Statistical analyses

Statistical analysis title	TEZ/IVA vs VX-445/TEZ/IVA TC
Comparison groups	TEZ/IVA v VX-445/TEZ/IVA TC
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed-effects model for repeated measure
Parameter estimate	LS mean difference
Point estimate	17.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.8
upper limit	23

Secondary: Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
-----------------	--

End point description:

Safety set included all subjects who received at least 1 dose of study drug in the TC treatment period.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8)

End point values	TEZ/IVA	VX-445/TEZ/IVA TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	55		
Units: Subjects				
Subjects with AEs	33	32		
Subjects with SAEs	1	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Observed Pre-Dose Concentration (Ctough) of VX-445, TEZ, TEZ Metabolite (M1-TEZ), and IVA

End point title	Observed Pre-Dose Concentration (Ctough) of VX-445, TEZ, TEZ Metabolite (M1-TEZ), and IVA
-----------------	---

End point description:

Pharmacokinetic analysis set included all subjects who received at least 1 dose of study drug in the TC treatment period. Here "n" signifies those subjects who were evaluable for this endpoint at specified time points and "99999" represents "Not Applicable" as data could not be calculated for the category with n=0 subject for 'TEZ/IVA' and indicates that data was not reported at the specified time point as all the observations were below the limit of quantitation for 'VX-445/TEZ/IVA TC' arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 and Week 4

End point values	TEZ/IVA	VX-445/TEZ/IVA TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	55		
Units: microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)				
VX-445: Day 1 (n= 0, 55)	99999 (± 99999)	99999 (± 99999)		
VX-445: Week 4 (n= 0, 54)	99999 (± 99999)	4.84 (± 2.59)		
TEZ: Day 1 (n= 50, 55)	1.71 (± 0.942)	1.60 (± 1.03)		
TEZ: Week 4 (n= 52, 55)	1.48 (± 0.829)	1.89 (± 0.974)		
M1-TEZ: Day 1 (n= 50, 55)	4.84 (± 1.71)	4.76 (± 1.78)		
M1-TEZ: Week 4 (n= 52, 55)	4.86 (± 1.74)	5.28 (± 2.04)		
IVA: Day 1 (n= 50, 55)	0.652 (± 0.399)	0.598 (± 0.428)		
IVA: Week 4 (n= 52, 55)	0.530 (± 0.297)	0.652 (± 0.542)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

Reporting groups

Reporting group title	TEZ/IVA
-----------------------	---------

Reporting group description:

Following a run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA for 4 weeks in the TC treatment period.

Reporting group title	VX-445/TEZ/IVA TC
-----------------------	-------------------

Reporting group description:

Following a run-in period of 4 weeks with TEZ/IVA, subjects received VX-445/TEZ/IVA for 4 weeks in the TC treatment period.

Serious adverse events	TEZ/IVA	VX-445/TEZ/IVA TC	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 52 (1.92%)	2 / 55 (3.64%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 52 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Infective pulmonary exacerbation of cystic fibrosis			
subjects affected / exposed	1 / 52 (1.92%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	TEZ/IVA	VX-445/TEZ/IVA TC	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 52 (48.08%)	24 / 55 (43.64%)	
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 52 (7.69%)	3 / 55 (5.45%)	
occurrences (all)	4	3	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 52 (3.85%)	3 / 55 (5.45%)	
occurrences (all)	2	3	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	3 / 52 (5.77%)	2 / 55 (3.64%)	
occurrences (all)	3	2	
Abdominal pain			
subjects affected / exposed	1 / 52 (1.92%)	3 / 55 (5.45%)	
occurrences (all)	1	3	
Nausea			
subjects affected / exposed	3 / 52 (5.77%)	1 / 55 (1.82%)	
occurrences (all)	3	1	
Respiratory, thoracic and mediastinal disorders			
Sputum increased			
subjects affected / exposed	3 / 52 (5.77%)	3 / 55 (5.45%)	
occurrences (all)	3	3	
Cough			
subjects affected / exposed	4 / 52 (7.69%)	8 / 55 (14.55%)	
occurrences (all)	4	8	
Haemoptysis			
subjects affected / exposed	5 / 52 (9.62%)	2 / 55 (3.64%)	
occurrences (all)	8	2	
Oropharyngeal pain			
subjects affected / exposed	0 / 52 (0.00%)	4 / 55 (7.27%)	
occurrences (all)	0	6	
Nasal congestion			

subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	3 / 55 (5.45%) 3	
Respiration abnormal subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	3 / 55 (5.45%) 3	
Infections and infestations			
Infective pulmonary exacerbation of cystic fibrosis subjects affected / exposed occurrences (all)	5 / 52 (9.62%) 5	0 / 55 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 52 (3.85%) 2	4 / 55 (7.27%) 4	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 52 (3.85%) 2	4 / 55 (7.27%) 4	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 April 2018	Updated study drug regimen, dosing guidance, dose and population rationale.
19 July 2018	Revised exclusion criteria.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported